ARNA - アリ―ナ・ファ―マシュ―ティカルズ （Arena Pharmaceuticals Inc.） アリ―ナ・ファ―マシュ―ティカルズARNAのチャート
ARNAの企業情報
| symbol | ARNA |
|---|---|
| 会社名 | Arena Pharmaceuticals Inc （アリ―ナ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アリーナ・ファーマシューティカルズ（Arena Pharmaceuticals Inc.）はバイオ医薬品会社である。同社は治療領域にわたって小分子薬物の開発に従事する。同社は、潰瘍性大腸炎の第II相評価におけるエトラサモード（APD334）、クローン病に関連する疼痛の治療のための第II相評価に入るAPD371、及び肺動脈性高血圧(PAH)の第II相評価におけるralinepag（APD811）の3つの主要治験臨床プログラムを有する。同社の医薬品であるLorcaserinは、体重管理の指標として米国と韓国で販売承認を受ける。同社の臨床開発における候補者には、自己免疫疾患のためのAPD334、血管疾患のためのralinepag及び疼痛のためのAPD371が含まれる。同社の協力プログラムには、認知症関連精神病のネロタンセリン、血栓性疾患のテマノグレル、中枢神経系（CNS）適応症の非公開孤児GPCRが含まれる。 アリ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。医薬品医療ニ―ズに対応するため、Gタンパク質共役型受容体を標的とする薬剤を開発、商品化する。同社が開発した肥満症治療剤「BELVIQ」は、米国食品医薬品局(FDA)に唯一承認された薬剤である。そのほか、肺動脈高血圧症の治療のためのAPD811など、研究開発中の薬剤候補がある。 Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas |
| 本社所在地 | 6154 Nancy Ridge Drive San Diego CA 92121 USA |
| 代表者氏名 | Tina Susan Nova ティナ・スーザン・ノヴァ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-453-7200 |
| 設立年月日 | 35521 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 106人 |
| url | www.arenapharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arna |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -98.92900 |
| 終値（lastsale） | 39.7 |
| 時価総額（marketcap） | 1959123103.3 |
| 時価総額 | 時価総額（百万ドル） 1962.084 |
| 売上高 | 売上高（百万ドル） 13.97000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1429.45 |
| 当期純利益 | 当期純利益（百万ドル） -112.12500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arena Pharmaceuticals Inc. revenues increased 62% to $5.7M. Net loss before extraordinary items increased 38% to $63M. Revenues reflect Royalty revenue increase from $0K to $1.6M Collaboration and other revenue increase of 17% to $4.2M. Higher net loss reflects Research and development increase of 39% to $44.7M (expense) General and administrative - increase of 41% to $16.6M (expense). |
ARNAのテクニカル分析
ARNAのニュース
Pfizer''s Newest Way To Rival Bristol Myers Squibb Might Surprise You 2022/03/11 17:13:04 Investor''s Business Daily
Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.
Pfizer acquires Arena Pharmaceuticals for $6.7bn 2022/03/11 17:06:00 Bizcommunity
Source: [[https://pixabay.com/photos/laboratory-apparatus-equipment-217041/ Pixabay]] Pfizer announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Read more… |
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals 2022/03/11 16:04:21 MarketWatch
Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer''s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer confirms HSR waiting period for Arena Pharmaceuticals deal expired (NASDAQ:ARNA) 2022/03/10 13:26:39 Seeking Alpha
Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA) is now expected…
Arena Pharma stock ticks higher on Nasdaq delisting notice for Pfizer deal (NASDAQ:ARNA) 2022/03/09 02:08:06 Seeking Alpha
Arena Pharmaceuticals (ARNA) rose 1.1% in after hours trading after a Nasdaq delisting notice indicated the company''s last trading day would be Thursday due to the completion of its sale…
Pfizer''s Newest Way To Rival Bristol Myers Squibb Might Surprise You 2022/03/11 17:13:04 Investor''s Business Daily
Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.
Pfizer acquires Arena Pharmaceuticals for $6.7bn 2022/03/11 17:06:00 Bizcommunity
Source: [[https://pixabay.com/photos/laboratory-apparatus-equipment-217041/ Pixabay]] Pfizer announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Read more… |
Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals 2022/03/11 16:04:21 MarketWatch
Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer''s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer confirms HSR waiting period for Arena Pharmaceuticals deal expired (NASDAQ:ARNA) 2022/03/10 13:26:39 Seeking Alpha
Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA) is now expected…
Arena Pharma stock ticks higher on Nasdaq delisting notice for Pfizer deal (NASDAQ:ARNA) 2022/03/09 02:08:06 Seeking Alpha
Arena Pharmaceuticals (ARNA) rose 1.1% in after hours trading after a Nasdaq delisting notice indicated the company''s last trading day would be Thursday due to the completion of its sale…
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript 2021/11/05 03:07:15 Seeking Alpha
Nuveen Asset Management LLC Increases Stock Holdings in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) 2021/11/03 10:40:45 Dakota Financial News
Nuveen Asset Management LLC increased its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 21.7% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 511,497 shares of the biopharmaceutical companys stock after purchasing an additional 91,083 shares during the period. Nuveen Asset Management LLCs holdings in Arena Pharmaceuticals were worth $34,885,000 as []
Atom Investors LP Invests $569,000 in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) 2021/11/02 16:08:44 Transcript Daily
Atom Investors LP bought a new position in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,350 shares of the biopharmaceutical companys stock, valued at approximately $569,000. Several other institutional investors and hedge funds []
Arena Pharmaceuticals (ARNA) to Release Quarterly Earnings on Thursday 2021/11/02 08:58:41 Dakota Financial News
Arena Pharmaceuticals (NASDAQ:ARNA) will issue its quarterly earnings data after the market closes on Thursday, November 4th. Analysts expect the company to announce earnings of ($2.42) per share for the quarter. Parties that are interested in participating in the companys conference call can do so using this link. Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly []